Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
Cardiac Disease

About this trial
This is an interventional prevention trial for Cardiac Disease focused on measuring Children, Pediatrics, Cardiac disease with potential for thromboembolic complications, Prophylactic treatment, Anticoagulant drugs
Eligibility Criteria
Inclusion Criteria:
- Is a child with cardiac disease who is at risk for thromboembolic complications and requires at least 3 months antithrombotic anticoagulant prophylaxis
Either one of the following:
a child with cardiac disease who has a history of cardiac shunt occlusion/thrombosis, with shunt still in place (secondary prevention).
OR
- a child with cardiac disease who requires (including those already taking, and those not yet taking) anticoagulation for primary prevention of TE.
Cardiac conditions known to significantly increase the risk of thrombosis (hence, indications for primary TE prevention) are defined in Antithrombotic Therapy and Prevention of Thrombosis. Some examples of cardiac conditions at risk of thrombosis are Fontan surgery, heart failure, Kawasaki disease, and Blalock-Taussig and Glenn surgery.
- Is a male or female child between 1 and <18 years of age (children between 38 weeks gestational age and 1 year of age will be included in the study, however, only after the safety and efficacy data of 50 subjects between 1 and <18 years of age in the edoxaban arm have been evaluated at the end of the 3-month treatment period)
- Has parent(s)/legal guardian(s) or legally acceptable representative who is informed and provides signed consent for the child, to participate in the study with edoxaban treatment. Pediatric participants with appropriate intellectual maturity will be required to sign an assent form in addition to the signed informed consent from the parent(s)/legal guardian(s) or any legally acceptable representative.
- If a female subject of childbearing potential, tests negative for pregnancy at Screening and consents to avoid becoming pregnant by using a locally approved contraception method throughout the study
Exclusion Criteria:
- Has evidence of symptomatic venous or arterial thrombosis and/or asymptomatic intracardiac thrombosis confirmed by a transthoracic echocardiogram during study screening period
- Has mechanical heart valve(s)
- Has active bleeding or high risk of bleeding contraindicating treatment with anticoagulant
- Takes antithrombotic therapy (other than low-dose aspirin) that is not protocol-related
- Administration of rifampin is prohibited during the study and subjects on concomitant use of rifampin are excluded
- Has any hepatic disease associated with coagulopathy leading to a clinically relevant bleeding risk
- Has estimated glomerular filtration rate (eGFR) <30% of normal for age and size
- Has stage 2 hypertension defined as blood pressure systolic and/or diastolic confirmed >99th percentile plus 5 mmHg
- Has thrombocytopenia or life expectancy less than three months
- Has had Fontan procedure with a history of or signs/symptoms suggestive of protein-losing enteropathy
- Is pregnant or breastfeeding
- Has a contraindication to the use of heparin and/or vitamin K antagonist (VKA)
- Has any condition that, as judged by the Investigator, would place the participant at increased risk of harm if he/she participated in the study, including contraindicated medications identified in the protocol
Sites / Locations
- University of Alabama at Birmingham
- Cardon Childrens Medical Center
- Cedars Sinai Medical Center (ECG)
- University of California-San Francisco Department of Pediatrics - Hematology/Oncology
- University of Florida College of Medicine
- Ann & Robert H. Lurie Children's Hospital of Chicago
- Rush University Medical Center
- Ochsner Medical Center
- Novant Health Heart and Vascular institute
- East Carolina Heart Institute @ ECU
- Wake Forest University Baptist Medical Center
- OU Health Sciences Center
- University of Virginia Health System
- Seattle Children's Research Institute
- Kepler Universitätsklinikum Med Campus IV
- McMaster Children's Hospital
- CHU Sainte-Justine
- McGill University Health Centre/Glen Site/Montreal Children's Hospital
- University Hospital Center Zagreb
- Zagazig University Hospital
- Alexandria Clinical Research Center, Faculty of Medicine
- Kasr Elainy School of Medicine, Abo Elreesh Hospital (Japanese Hospital), Ali Basha Ibrahim ST Faculty of Medicine Cairo University
- Ain Shams University Hospital
- Suez Canal University Hospital
- Hôpital Des Enfants, Bâtiment Modulaire
- Pediatric and Congenital Cardiology and Pulmonology Department; Arnaud De Villeneuve University Hospital
- Pediatric Cardiology Department, Hospital Necker Enfants Malades, APHP, Université Paris Descartes
- Gottsegen Gyorgy Orszagos Kardiologiai Intezet
- Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
- Nirmal Hospital Private Limited
- Institute of Child Health
- Soroka University Medical Center
- Hadassah University Hospital - Ein Kerem
- Sheba Medical Center
- Children's Heart Centre at the American University of Beirut Medical Center
- Hotel Dieu de France Hospital
- Hospital Universitari Vall d'Hebron
- Erciyes University Medical Faculty, Department of Children Hospital
- Hacettepe University Medical Faculty
- Istanbul University Istanbul Medical Faculty
- Ege University Faculty of Medicine Department of Child Health and Diseases
- Izmir-Dr. Behçet Uz. Pediatric Diseases and Surgery Training and Research Hospital- Izmir Dr. Behcet Uz Cocuk Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
- Communal Institution Dnipropetrovsk Regional Pediatric Clinical Hospital of Dnipropetrovsk Regional Council, State Institution Dnipropetrovsk Medical Academy of MoH of Ukraine
- Communal Healthcare Institution Regional Pediatric Clinical Hospital, Kharkiv National Medical University
- Vynnitsa Regional Children Clinical Hospital Policlinic Dept
- Royal Brompton Hospital
- Glenfield Hospital
- Ward 2B, Royal Hospital for Children
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Edoxaban
Standard of Care (SOC)
Two out of three participants will be randomized for treatment with edoxaban solution or tablets
One out of three participants will be randomized for treatment with the institution's SOC regimen